Therapy-related AML (tAML) is one of the most prevalent secondary malignant neoplasms in paediatric cancer survivors. Estimates of incidence and association with causative chemotherapeutic agents are mainly based on epidemiological data. Individual courses revealing the exact timing of the first clone appearance and its development under treatment are limited owing to the overall low incidence, which does not justify repeated bone marrow sampling in order to detect the occurrence of potentially leukemic cells.
Here we report a unique case of tAML arising after neuroblastoma treatment that was tracked by the presence of a MLL-DCP1A translocation. Kinetics of the malignant clone implied disease initiation by the first etoposide doses, allowed a quantitative follow-up during chemotherapy and suggested clone eradication by a GvL reaction.
A 3-year 9-months-old girl presented with N-Myc -, del1p36 + , MIBG + disseminated neuroblastoma and received treatment on the NB2004 trial protocol (NCT00410631). Chemotherapy was initiated with two N8 cycles (topotecan, cyclophosphamide and etoposide) as the experimental arm of a trial assessing topotecan for treatment of high-risk neuroblastoma 1 followed by three N5 (cisplatin, etoposide and vindesine), two N6 (vincristine, dacarbacin, ifosfamide and doxorubicine) and a third N8 cycle, thoracotomic tumour resection, 131-I-MIBG treatment and myeloablative megatherapy (melphalan, etoposide and carboplatin) and subsequent autologous stem cell transplantation (ASCT). Retinoid acid (RA)-maintenance therapy was started 63 days thereafter. 2 Restaging for persistent neuroblastoma was negative, but progressive neutropenia developed despite RA-dose adjustment ( Figure 1a) .
A diagnostic bone marrow aspiration 216 days after ASCT revealed tAML FAB M4 with the expression of CD33, CD38, CD14, CD15, CD45, CXCR4 and cytoplasmic MPO. Treatment protocol AML-BFM 2004 was initiated with prolonged bone marrow aplasia observed after the second L-DNR/FLAG. 3 Unrelated bone marrow transplantation was initiated by conditioning with thiotepa, fludarabine, treosulfan and antithymocyte globulin. GvHD prophylaxis with cyclosporin A (CSA) started at day-1. In addition, 10 mg/m 2 MTX were given on days +1, +3 and +6. Grade II skin GvHD and grade I gut GvHD developed around day 32 after allogeneic transplantation, but responded within days to shortterm systemic steroids. Few other individuals with MLL-rearranged leukaemia after neuroblastoma treatment have been reported in detail; outcome was predominantly unfavourable in these cases. [4] [5] [6] The occurrence of AML within o 2 years after treatment with etoposide was highly suggestive of the presence of MLL-rearrangements. Cytogenetic analysis (46,XX,t(3;11)(p21;q23)) confirmed an 11q23 aberration with translocation to 3p21 and interphase split-FISH demonstrated involvement of MLL (Figure 1b) . Genomic LDI-PCR 7 identified the fusion in intron 6 of DCP1 A (DCP1 decapping enzyme homolog A; Figure 1c ). In frame MLL-DCP1A and DCP1A-MLL fusion transcripts were amplified by RT-PCR. DCP1A is predominantly cytoplasmic as part of a protein complex involved in degradation of mRNAs. 8 Upon stimulation by TGFB1 and interaction with SMAD4, it becomes nuclear contributing to the transactivation of TGF-α target genes.
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DCP1A is a novel MLL fusion partner in AML. The in vitro transforming capacity of MLL-DCP1A was weaker than the more common MLL-ENL fusion but it could nevertheless be clearly verified by colony formation in retroviral transduction-replating assays 10 ( Figure 1d ). The cumulative sampling of bone marrow during preceding neuroblastoma treatment offered the unique possibility to quantitatively backtrack the origin of the tAML by quantitative real-time PCR using the genomic MLL-DCP1A breakpoint as a molecular marker. A low-grade presence of the leukemic clone (10 − 4 in mononuclear cells) was already detectable in bone marrow at day 67 after the first two N8 cycles consisting of topotecan 1 mg/m 2 per day (day 1-7), cyclophosphamide 100 mg/m 2 per day (day 1-7) and etoposide 100 mg/m 2 per day (day 8-10). Topotecan is a topoisomerase I inhibitor but an increased carcinogenic risk for malignancies with chromosomal aberrations after topotecan treatment has not yet been observed. Secondary haematological malignancies induced by alkylating agents, such as cyclophosphamide, typically occur with a latency of 5-7 years and show cytogenetic abnormalities involving chromosomes 5 and 7. Topoisomerase-II inhibitors like etoposides and anthracyclines induce secondary leukaemia with a short latency period of 2-3 years that frequently carry translocations involving 11q and 21q suggesting a causative involvement in the current case. Breakpoint characteristics, microhomology and duplication of the GATCA nucleotides in the reciprocal DCP1A-MLL fusion document a NHEJ repair signature, consistent with a topoisomerase II-related rearrangement. The MLL-DCP1A breakpoint in this particular case occurred in position 1181 of the MLL breakpoint cluster region, 5 Kb distant from the localization of a topoisomerase II recognition site, a hot-spot of tAML.
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+ cell selection from mobilized peripheral stem cells was applied as purging strategy for residual neuroblastoma cells according to the treatment protocol. Unfortunately, MLL-DCP1 A myeloid cells were also enriched by this procedure (Figure 1a) . Despite intensive chemotherapy treatment of neuroblastoma the malignant clone expanded and it was only partially reduced after MIBG and high-dose chemotherapy preceding ASCT. In contrast, cells experimentally transformed by MLL-DCP1A alone responded to all-trans RA treatment with proliferation arrest and terminal differentiation (Figures 1e and f) suggesting the accumulation of additional mutations beyond the MLL translocation.
During routine immune suppression by CSA after allogeneic transplantation, MRD was detectable in the range of 10 − 3 to 10
where normal chimaerism analysis by STR-repeat PCR could not detect this developing molecular relapse because of the methodological-sensitivity limit. Facing an imminent molecular relapse it was decided to stop CSA ahead of schedule to allow a more intense GvL effect. Indeed, tapering and eventually discontinuation of CSA resulted in gradual MRD reduction leading to a permanent molecular remission for 5 years (Figure 1a ). This example underscores the benefit of highly sensitive quantitative PCR techniques using the unique fusion gene as molecular marker for MRD detection. 12 Alternatively, routine methods are limited by their sensitivity (morphology and FISH) or their ability to discriminate definitively between blasts and benign progenitor cells in regenerating bone marrow (flow cytometry and gene-expression profiling). With the development of patient-specific MRD assays, clinical management and biological understanding of high-risk leukaemia may benefit from precise monitoring of therapy effects after application of novel agents and immune interventions.
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